
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7958651/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. Biological Psychiatry, 2008, 63, 801-808.	1.3	883
2	Widespread and sustained cognitive deficits in alcoholism: a metaâ€analysis. Addiction Biology, 2013, 18, 203-213.	2.6	433
3	Cognitive deficits in individuals with methamphetamine use disorder: A meta-analysis. Addictive Behaviors, 2018, 80, 154-160.	3.0	219
4	Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis. Schizophrenia Research, 2013, 151, 43-47.	2.0	190
5	Mobile Apps for Mental Health Issues: Meta-Review of Meta-Analyses. JMIR MHealth and UHealth, 2020, 8, e17458.	3.7	169
6	Cocaine and Cognition. Journal of Addiction Medicine, 2014, 8, 368-376.	2.6	159
7	Cannabidiol in Humans—The Quest for Therapeutic Targets. Pharmaceuticals, 2012, 5, 529-552.	3.8	155
8	Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. European Psychiatry, 2007, 22, 104-115.	0.2	139
9	Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis. Schizophrenia Research, 2008, 100, 242-251.	2.0	128
10	Pain facilitation and pain inhibition during conditioned pain modulation in fibromyalgia and in healthy controls. Pain, 2016, 157, 1704-1710.	4.2	123
11	Human evidence of a supraâ€spinal modulating role of dopamine on pain perception. Synapse, 2009, 63, 390-402.	1.2	118
12	The Deficit of Pain Inhibition in Fibromyalgia Is More Pronounced in Patients With Comorbid Depressive Symptoms. Clinical Journal of Pain, 2009, 25, 123-127.	1.9	118
13	A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychological Medicine, 2006, 36, 431-440.	4.5	108
14	Virtual reality therapy for refractory auditory verbal hallucinations in schizophrenia: A pilot clinical trial. Schizophrenia Research, 2018, 197, 176-181.	2.0	103
15	Pain Inhibition Is Deficient in Chronic Widespread Pain but Normal in Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, 219-224.	2.2	94
16	DRD3 Ser9Gly Polymorphism Is Related to Thermal Pain Perception and Modulation in Chronic Widespread Pain Patients and Healthy Controls. Journal of Pain, 2009, 10, 969-975.	1.4	91
17	Hypoalgesia in schizophrenia is independent of antipsychotic drugs: A systematic quantitative review of experimental studies. Pain, 2008, 138, 70-78.	4.2	88
18	Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, 604-610.	2.2	86

#	Article	IF	CITATIONS
19	Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study. Rheumatology International, 2009, 29, 509-515.	3.0	74
20	Pain perception in schizophrenia: No changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. Journal of Psychiatric Research, 2008, 42, 1010-1016.	3.1	67
21	CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain and Cognition, 2005, 59, 38-42.	1.8	63
22	Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Current Medical Research and Opinion, 2006, 22, 1277-1285.	1.9	63
23	Sex differences in effective fronto-limbic connectivity during negative emotion processing. Psychoneuroendocrinology, 2015, 62, 180-188.	2.7	62
24	No relationship between the ins del polymorphism of the serotonin transporter promoter and pain perception in fibromyalgia patients and healthy controls. European Journal of Pain, 2010, 14, 742-746.	2.8	59
25	Evidence on Virtual Reality–Based Therapies for Psychiatric Disorders: Meta-Review of Meta-Analyses. Journal of Medical Internet Research, 2020, 22, e20889.	4.3	59
26	Pain relief through expectation supersedes descending inhibitory deficits in fibromyalgia patients. Pain, 2009, 145, 18-23.	4.2	55
27	Clozapine, quetiapine and olanzapine among addicted schizophrenic patients. International Clinical Psychopharmacology, 2003, 18, 121-132.	1.7	54
28	Symptomatic and functional outcomes of substance use disorder persistence 2 years after admission to a first-episode psychosis program. Psychiatry Research, 2017, 247, 113-119.	3.3	54
29	Loss anticipation and outcome during the <i>Monetary Incentive Delay Task</i> : a neuroimaging systematic review and meta-analysis. PeerJ, 2018, 6, e4749.	2.0	54
30	The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. Psychiatry Research, 2018, 268, 189-192.	3.3	53
31	Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Current Medical Research and Opinion, 2008, 24, 1017-1024.	1.9	49
32	Is the Deficit in Pain Inhibition in Fibromyalgia Influenced by Sleep Impairments?. Open Rheumatology Journal, 2012, 6, 296-302.	0.2	46
33	Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of Psychopharmacology, 2008, 22, 262-269.	4.0	45
34	Schizophrenia and serious violence: A clinical-profile analysis incorporating impulsivity and substance-use disorders. Schizophrenia Research, 2011, 130, 234-237.	2.0	44
35	Pain Perception in Schizophrenia: Evidence of a Specific Pain Response Profile. Pain Medicine, 2012, 13, 1571-1579.	1.9	44
36	Self-evaluation and objective assessment of cognition in major depression and attention deficit disorder: Implications for clinical practice. Comprehensive Psychiatry, 2016, 70, 53-64.	3.1	43

#	Article	IF	CITATIONS
37	Cognitive biases in individuals with psychotic-like experiences: A systematic review and a meta-analysis. Schizophrenia Research, 2020, 222, 10-22.	2.0	42
38	Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Canadian Journal of Psychiatry, 2015, 60, S26-34.	1.9	42
39	The Psychometric Properties of a Short UPPS-P Impulsive Behavior Scale Among Psychiatric Patients Evaluated in an Emergency Setting. Frontiers in Psychiatry, 2019, 10, 139.	2.6	41
40	Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Research, 2012, 200, 237-241.	3.3	40
41	Persistency of Cannabis Use Predicts Violence following Acute Psychiatric Discharge. Frontiers in Psychiatry, 2017, 8, 176.	2.6	40
42	Meta-Analysis of Depressive Symptoms in Dual-Diagnosis Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2007, 41, 792-799.	2.3	39
43	Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders. International Clinical Psychopharmacology, 2011, 26, 183-192.	1.7	39
44	Neurofunctional abnormalities in antisocial spectrum: A meta-analysis of fMRI studies on Five distinct neurocognitive research domains. Neuroscience and Biobehavioral Reviews, 2020, 119, 168-183.	6.1	38
45	Cannabis and Psychosis: What is the Link?. Journal of Psychoactive Drugs, 2007, 39, 131-142.	1.7	37
46	One-year randomized trial comparing virtual reality-assisted therapy to cognitive–behavioral therapy for patients with treatment-resistant schizophrenia. NPJ Schizophrenia, 2021, 7, 9.	3.6	36
47	Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A meta-analysis. Schizophrenia Research, 2009, 113, 181-188.	2.0	35
48	Current Practices of Electroconvulsive Therapy in Mental Disorders. Journal of ECT, 2021, 37, 119-127.	0.6	35
49	Antipsychotic Agents for the Treatment of Substance Use Disorders in Patients With and Without Comorbid Psychosis. Journal of Clinical Psychopharmacology, 2010, 30, 417-424.	1.4	34
50	Modulation of the Endocannabinoid System: Vulnerability Factor and New Treatment Target for Stimulant Addiction. Frontiers in Psychiatry, 2013, 4, 109.	2.6	34
51	The Prevalence of Electroconvulsive Therapy Use Since 1973. Journal of ECT, 2016, 32, 236-242.	0.6	34
52	Cannabis use and violence in patients with severe mental illnesses: A meta-analytical investigation. Psychiatry Research, 2019, 274, 42-48.	3.3	34
53	Reversing the Atypical Valuation of Drug and Nondrug Rewards in Smokers Using Multimodal Neuroimaging. Biological Psychiatry, 2017, 82, 819-827.	1.3	33
54	The Impact of Pain Invisibility on Patient-Centered Care and Empathetic Attitude in Chronic Pain Management. Pain Research and Management, 2018, 2018, 1-8.	1.8	33

#	Article	IF	CITATIONS
55	Functional Neuroimaging Predictors of Self-Reported Psychotic Symptoms in Adolescents. American Journal of Psychiatry, 2017, 174, 566-575.	7.2	32
56	Limbic Hyperactivity in Response to Emotionally Neutral Stimuli in Schizophrenia: A Neuroimaging Meta-Analysis of the Hypervigilant Mind. American Journal of Psychiatry, 2019, 176, 1021-1029.	7.2	30
57	Predicting and preventing symptom onset and relapse in schizophrenia—A metareview of current empirical evidence Journal of Abnormal Psychology, 2019, 128, 840-854.	1.9	30
58	Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic metaâ€review of metaâ€analyses. Addiction, 2022, 117, 1857-1870.	3.3	30
59	Temporal Summation of Pain Is Not Amplified in a Large Proportion of Fibromyalgia Patients. Pain Research and Treatment, 2012, 2012, 1-6.	1.7	29
60	Association Between the Use of Cannabis and Physical Violence in Youths: A Meta-Analytical Investigation. American Journal of Psychiatry, 2020, 177, 619-626.	7.2	29
61	Endocannabinoids and Schizophrenia. Pharmaceuticals, 2010, 3, 3101-3126.	3.8	27
62	A Deficit in Peripheral Serotonin Levels in Major Depressive Disorder but Not in Chronic Widespread Pain. Clinical Journal of Pain, 2011, 27, 529-534.	1.9	27
63	Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1695-1698.	4.8	26
64	A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. Nature Protocols, 2022, 17, 567-595.	12.0	26
65	The Paradox of Quetiapine in Obsessive-Compulsive Disorder. CNS Spectrums, 2005, 10, 356-361.	1.2	25
66	Developmental joint trajectories of anxiety-depressive trait and trait-aggression: implications for co-occurrence of internalizing and externalizing problems. Psychological Medicine, 2020, 50, 1338-1347.	4.5	25
67	Emotionally Neutral Stimuli Are Not Neutral in Schizophrenia: A Mini Review of Functional Neuroimaging Studies. Frontiers in Psychiatry, 2016, 7, 115.	2.6	24
68	Abnormal effective fronto-limbic connectivity during emotion processing in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 72, 1-8.	4.8	24
69	Exploration of the dialogue components in <scp>A</scp> vatar <scp>T</scp> herapy for schizophrenia patients with refractory auditory hallucinations: <scp>A</scp> content analysis. Clinical Psychology and Psychotherapy, 2018, 25, 878-885.	2.7	24
70	Longâ€acting antipsychotic medication as firstâ€line treatment of firstâ€episode psychosis with comorbid substance use disorder. Microbial Biotechnology, 2020, 14, 69-79.	1.7	24
71	Add-on Treatment of Quetiapine for Fibromyalgia. Journal of Clinical Psychopharmacology, 2012, 32, 684-687.	1.4	23
72	Violence and Cannabis Use: A Focused Review of a Forgotten Aspect in the Era of Liberalizing Cannabis. Frontiers in Psychiatry, 2020, 11, 567887.	2.6	23

#	Article	IF	CITATIONS
73	Working memory and depressive symptoms in patients with schizophrenia and substance use disorders. Cognitive Neuropsychiatry, 2008, 13, 357-366.	1.3	22
74	Questioning the Specificity of ASRS-v1.1 to Accurately Detect ADHD in Substance Abusing Populations. Journal of Attention Disorders, 2012, 16, 661-663.	2.6	22
75	Paradoxical Cognitive Capacities in Dual Diagnosis Schizophrenia: The Quest for Explanatory Factors. Journal of Dual Diagnosis, 2012, 8, 35-47.	1.2	22
76	Cigarette Cravings, Impulsivity, and the Brain. Frontiers in Psychiatry, 2015, 6, 125.	2.6	22
77	Avatar Therapy for Persistent Auditory Verbal Hallucinations in an Ultra-Resistant Schizophrenia Patient: A Case Report. Frontiers in Psychiatry, 2018, 9, 131.	2.6	22
78	Mobile Intervention for Individuals With Psychosis, Dual Disorders, and Their Common Comorbidities: A Literature Review. Frontiers in Psychiatry, 2019, 10, 302.	2.6	22
79	Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: A voxel-based morphometry study. Psychiatry Research - Neuroimaging, 2007, 154, 275-279.	1.8	21
80	Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement Disorders, 2010, 25, 2188-2194.	3.9	21
81	Sex Differences and Menstrual Cycle Phase-Dependent Modulation of Craving for Cigarette: An fMRI Pilot Study. Psychiatry Journal, 2014, 2014, 1-7.	1.5	21
82	Neural Circuitry of Impulsivity in a Cigarette Craving Paradigm. Frontiers in Psychiatry, 2013, 4, 67.	2.6	20
83	Increased ventro-medial prefrontal activations in schizophrenia smokers during cigarette cravings. Schizophrenia Research, 2016, 173, 30-36.	2.0	20
84	Distinct patterns of prefrontal cortical disengagement during inhibitory control in addiction: A meta-analysis based on population characteristics. Neuroscience and Biobehavioral Reviews, 2021, 127, 255-269.	6.1	20
85	Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect―of Schizophrenia. Frontiers in Psychiatry, 2012, 3, 85.	2.6	19
86	Male Inmate Profiles and Their Biological Correlates. Canadian Journal of Psychiatry, 2014, 59, 441-449.	1.9	19
87	Anterior cingulate hyperactivations during negative emotion processing among men with schizophrenia and a history of violent behavior. Neuropsychiatric Disease and Treatment, 2016, 12, 1397.	2.2	19
88	A Meta-analysis of Mindfulness-Based Interventions in Adults with Attention-Deficit Hyperactivity Disorder: Impact on ADHD Symptoms, Depression, and Executive Functioning. Mindfulness, 2020, 11, 2669-2681.	2.8	19
89	Acute effects of partial CB1 receptor agonists on cognition – A meta-analysis of human studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110063.	4.8	19
90	Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. Behavioural Brain Research, 2010, 208, 163-168.	2.2	18

#	Article	IF	CITATIONS
91	Emotion processing in treatment-resistant schizophrenia patients treated with clozapine: An fMRI study. Schizophrenia Research, 2015, 168, 377-380.	2.0	18
92	Processing of social emotion in patients with schizophrenia and substance use disorder: An fMRI study. Social Neuroscience, 2007, 2, 106-116.	1.3	17
93	Anhedonia and Social Adaptation Predict Substance Abuse Evolution in Dual Diagnosis Schizophrenia. American Journal of Drug and Alcohol Abuse, 2008, 34, 75-82.	2.1	17
94	Exploring the Benefits of Virtual Reality-Assisted Therapy Following Cognitive-Behavioral Therapy for Auditory Hallucinations in Patients with Treatment-Resistant Schizophrenia: A Proof of Concept. Journal of Clinical Medicine, 2020, 9, 3169.	2.4	17
95	The Drug Abuse Screening Test preserves its excellent psychometric properties in psychiatric patients evaluated in an emergency setting. Addictive Behaviors, 2017, 64, 165-170.	3.0	16
96	Reduced dorsolateral prefrontal cortex activation during affective Go/NoGo in violent schizophrenia patients: An fMRI study. Schizophrenia Research, 2018, 197, 249-252.	2.0	16
97	Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting. Frontiers in Psychiatry, 2020, 11, 628.	2.6	16
98	Down and High: Reflections Regarding Depression and Cannabis. Frontiers in Psychiatry, 2021, 12, 625158.	2.6	16
99	History of Suicide Attempt Is Associated with Reduced Medial Prefrontal Cortex Activity during Emotional Decision-Making among Men with Schizophrenia: An Exploratory fMRI Study. Schizophrenia Research and Treatment, 2018, 2018, 1-8.	1.5	15
100	Comprehensive review on virtual reality for the treatment of violence: implications for youth with schizophrenia. NPJ Schizophrenia, 2019, 5, 11.	3.6	15
101	Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. International Clinical Psychopharmacology, 2020, 35, 221-228.	1.7	15
102	Cannabis and Cognitive Functioning: From Acute to Residual Effects, From Randomized Controlled Trials to Prospective Designs. Frontiers in Psychiatry, 2021, 12, 596601.	2.6	15
103	Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 997-1000.	4.8	14
104	Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile. Clinical Therapeutics, 2011, 33, 1853-1867.	2.5	14
105	Cannabis abuse is associated with better emotional memory in schizophrenia: A functional magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 2013, 214, 24-32.	1.8	14
106	Psychopathology in Substance Use Disorder Patients with and without Substance-Induced Psychosis. Journal of Addiction, 2015, 2015, 1-7.	0.9	14
107	The therapeutic processes of avatar therapy: A content analysis of the dialogue between treatmentâ€resistant patients with schizophrenia and their avatar. Clinical Psychology and Psychotherapy, 2021, 28, 500-518.	2.7	14
108	Interpersonal Risk Factors for Suicide in Cocaine Dependence: Association with Selfâ€Esteem, Personality Traits, and Childhood Abuse. Suicide and Life-Threatening Behavior, 2020, 50, 867-883.	1.9	13

#	Article	IF	CITATIONS
109	Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case–Control Trial with Quetiapine. Frontiers in Psychiatry, 2011, 2, 22.	2.6	12
110	Where there's smoke, there's fire: The brain reactivity of chronic smokers when exposed to the negative value of smoking. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 66-73.	4.8	12
111	Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 147-154.	3.2	12
112	Reward-related decision-making in schizophrenia: A multimodal neuroimaging study. Psychiatry Research - Neuroimaging, 2019, 286, 45-52.	1.8	12
113	Can Social Anxiety Impact Facial Emotion Recognition in Schizophrenia?. Journal of Nervous and Mental Disease, 2019, 207, 140-144.	1.0	12
114	A systematic review of longitudinal studies investigating the impact of cannabis use in patients with psychotic disorders. Expert Review of Neurotherapeutics, 2021, 21, 779-791.	2.8	12
115	The Neural Correlates of Mental Rotation Abilities in Cannabis-Abusing Patients with Schizophrenia: An fMRI Study. Schizophrenia Research and Treatment, 2013, 2013, 1-10.	1.5	11
116	Executive-affective connectivity in smokers viewing anti-smoking images: An fMRI study. Psychiatry Research - Neuroimaging, 2014, 224, 262-268.	1.8	11
117	Violent Behavior Is Associated With Emotion Salience Network Dysconnectivity in Schizophrenia. Frontiers in Psychiatry, 2020, 11, 143.	2.6	11
118	Functional connectivity abnormalities of the long-axis hippocampal subregions in schizophrenia during episodic memory. NPJ Schizophrenia, 2021, 7, 19.	3.6	11
119	Impaired attentional and socio-affective networks in subjects with antisocial behaviors: a meta-analysis of resting-state functional connectivity studies. Psychological Medicine, 2021, 51, 1249-1259.	4.5	11
120	Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 118, 110575.	4.8	11
121	Toxic Psychoses as Pharmacological Models of Schizophrenia. Current Psychiatry Reviews, 2005, 1, 23-32.	0.9	10
122	Increased Connectivity Between the Nucleus Accumbens and the Default Mode Network in Patients With Schizophrenia During Cigarette Cravings. Journal of Dual Diagnosis, 2019, 15, 8-15.	1.2	10
123	<i>In vivo</i> immunomodulatory effects of antipsychotics on inflammatory mediators: A review. Advances in Bioscience and Biotechnology (Print), 2012, 03, 551-565.	0.7	10
124	Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis. Psychopharmacology Bulletin, 2018, 48, 25-61.	0.0	9
125	Assessing Patient-Centred Care for Chronic Pain: Validation of a New Research Paradigm. Pain Research and Management, 2015, 20, 183-188.	1.8	8
126	The psychometric properties of the Life History of Aggression evaluated in patients from a psychiatric emergency setting. Psychiatry Research, 2017, 257, 485-489.	3.3	8

#	Article	IF	CITATIONS
127	Cognitive dysfunction and cerebral volumetric deficits in individuals with Alzheimer's disease, alcohol use disorder, and dual diagnosis. Psychiatry Research - Neuroimaging, 2021, 317, 111380.	1.8	8
128	Distinct pathological profiles of inmates showcasing cluster B personality traits, mental disorders and substance use regarding violent behaviors. Psychiatry Research, 2018, 260, 371-378.	3.3	7
129	Pleasant Pain Relief and Inhibitory Conditioned Pain Modulation: A Psychophysical Study. Pain Research and Management, 2018, 2018, 1-8.	1.8	7
130	Developmental multi-trajectory of irritability, anxiety, and hyperactivity as psychological markers of heterogeneity in childhood aggression. Psychological Medicine, 2022, 52, 241-250.	4.5	7
131	Comorbidity Profiles of Psychotic Patients in Emergency Psychiatry. Journal of Dual Diagnosis, 2020, 16, 260-270.	1.2	7
132	Increased cingulo-orbital connectivity is associated with violent behaviours in schizophrenia. Journal of Psychiatric Research, 2022, 147, 183-189.	3.1	7
133	Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients. Community Mental Health Journal, 2013, 49, 317-322.	2.0	6
134	Increased spinal pain sensitization in major depressive disorder: A pilot study. Psychiatry Research, 2016, 246, 756-761.	3.3	6
135	Berkson's bias in biobank sampling in a specialised mental health care setting: a comparative cross-sectional study. BMJ Open, 2020, 10, e035088.	1.9	6
136	Use of Automated Thematic Annotations for Small Data Sets in a Psychotherapeutic Context: Systematic Review of Machine Learning Algorithms. JMIR Mental Health, 2021, 8, e22651.	3.3	6
137	Meta-analytical transdiagnostic neural correlates in common pediatric psychiatric disorders. Scientific Reports, 2022, 12, 4909.	3.3	6
138	Rapid screening for cognitive deficits in attention deficit and hyperactivity disorders with the screen for cognitive impairment in psychiatry. ADHD Attention Deficit and Hyperactivity Disorders, 2019, 11, 139-147.	1.7	5
139	<p>Medial Orbitofrontal De-Activation During Tonic Cold Pain Stimulation: A fMRI Study Examining the Opponent-Process Theory</p> . Journal of Pain Research, 2020, Volume 13, 1335-1347.	2.0	5
140	Functional Connectivity During Visuospatial Processing in Schizophrenia: A Classification Study Using Lasso Regression. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1077-1087.	2.2	5
141	Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. NPJ Schizophrenia, 2022, 8, 29.	3.6	5
142	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	1.9	5
143	Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opinion on Pharmacotherapy, 2010, 11, 2947-2951.	1.8	4
144	Avatar Therapy for persistent auditory verbal hallucinations: a case report of a peer research assistant on his path toward recovery. Psychosis, 2018, 10, 213-219.	0.8	4

#	Article	IF	CITATIONS
145	Limbic Hyperactivity in Response to Emotionally Neutral Stimuli in Schizophrenia: Response to Rasetti et al American Journal of Psychiatry, 2020, 177, 640-641.	7.2	4
146	Aggression and delinquent behavior in a large representative sample of high school students: Cannabis use and victimization as key discriminating factors. Psychiatry Research, 2021, 296, 113640.	3.3	4
147	The processing of angry faces in schizophrenia patients with a history of suicide: An fMRI study examining brain activity and connectivity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 107, 110253.	4.8	4
148	Multiple developmental pathways underlying conduct problems: A multitrajectory framework. Development and Psychopathology, 2022, 34, 1115-1124.	2.3	4
149	Drugs of abuse and psychiatric disorders: Neurobiological and clinical aspects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 52, 1-3.	4.8	3
150	Anandamide Is Involved in Appetite-Related Amygdala Hyperactivations in Schizophrenia Patients Treated With Olanzapine. Journal of Clinical Psychopharmacology, 2015, 35, 82-83.	1.4	3
151	Does theory of mind predict specific domains of social functioning in individuals following a first episode psychosis?. Psychiatry Research, 2021, 301, 113933.	3.3	3
152	Assessing patient-centered care: Validation of the French Version of the Patient-Practitioner Orientation Scale (PPOS). European Journal for Person Centered Healthcare, 2015, 3, 295.	0.3	3
153	Is the Mood Disorder Questionnaire an appropriate screening tool in detecting bipolar spectrum disorder among substance use populations?. American Journal of Drug and Alcohol Abuse, 2011, 37, 79-81.	2.1	2
154	Is there a binding deficit in working memory in patients with schizophrenia? A meta-analysis. Schizophrenia Research, 2014, 158, 142-145.	2.0	2
155	Impaired Coupling between the Dorsomedial Prefrontal Cortex and the Amygdala in Schizophrenia Smokers Viewing Anti-smoking Images. Frontiers in Psychiatry, 2017, 8, 109.	2.6	2
156	The Canadian Network for Research in Schizophrenia and Psychoses: A Nationally Focused Approach to Psychosis and Schizophrenia Research. Canadian Journal of Psychiatry, 2021, , 070674372110091.	1.9	2
157	Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy. Psychiatry Research, 2021, 305, 114199.	3.3	2
158	Development of the French version of the Davos Assessment of Cognitive Biases Scale in a nonâ€clinical sample of young adults. Microbial Biotechnology, 2022, , .	1.7	2
159	Neural alterations of emotion processing in atypical trajectories of psychotic-like experiences. NPJ Schizophrenia, 2022, 8, .	3.6	2
160	Impact of early use of long-acting injectable antipsychotics on functional outcome in first episode psychosis: a 3-year longitudinal study. International Journal of Psychiatry in Clinical Practice, 2023, 27, 25-34.	2.4	2
161	Neuroimaging of cigarette cravings: individual differences matter. Addiction, 2015, 110, 204-205.	3.3	1
162	Markedly Reduced Thermal Pain Perception in a Schizoaffective Patient with Tardive Dyskinesia. Case Reports in Psychiatry, 2016, 2016, 1-3.	0.5	1

#	Article	IF	CITATIONS
163	Psychosocial Profiles of Patients Admitted to Psychiatric Emergency Services: Results from the Signature Biobank Project. Canadian Journal of Psychiatry, 2022, 67, 380-390.	1.9	1
164	Des repÃ <sup>¨</sup> res pour la conception des appsÂ?. Sante Mentale Au Quebec, 0, 46, 119-134.	0.1	1
165	The Role of Appetitive and Aversive Smoking Cues in Tobacco Use Disorder with a Focus on fMRI. , 2016, , 291-304.		1
166	Editorial: Purple Haze: Issues on Cannabis Legalization. Frontiers in Psychiatry, 2021, 12, 796032.	2.6	1
167	Striatum Inhibition: Clues for Cocaine Addiction Therapy. Canadian Journal of Neurological Sciences, 2014, 41, 664-665.	0.5	О
168	Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders― Frontiers in Behavioral Neuroscience, 2015, 9, 210.	2.0	0
169	Inflammatory alterations in dual diagnosis patients with schizophrenia and substance use disorders. FASEB Journal, 2011, 25, .	0.5	Ο
170	The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal. Canadian Journal of Psychiatry, 2015, 60, S1-4.	1.9	0
171	The Potential Paradoxical Neurocognitive Effects of Cannabis Use in Patients with Psychotic Disorders: A Critical Meta-Review of Meta-Analytical Evidence. Cannabis and Cannabinoid Research, 0, ,	2.9	Ο